DailyStocks Stock Article Search

https://www.fool.com/investing/2020/04/01/do-clinical-trial-delays-mean-trouble-for-pharmace.aspx?source=iedfolrf0000001 Apr 01, 2020 - Postponed clinical trials might mean a longer time-to-market for certain drugs. 0

http://www.zacks.com/stock/news/847731/buy-this-high-yield-large-cap-pharma-stock-for-income-amid-coronavirus?cid=CS-ZC-FT-video_blog-847731 Mar 31, 2020 - AbbVie (ABBV) stock popped on Tuesday. This is part of the global pharmaceutical giant's larger 20% surge in the last week as the market tries to mount a comeback amid the coronavirus uncertainty... 0

https://www.fool.com/investing/2020/03/31/eli-lilly-licenses-immunology-drugs-for-up-to-880.aspx?source=iedfolrf0000001 Mar 31, 2020 - The pharma giant will develop and market up to four drugs from the pipeline of privately-held Sitryx. 0

http://www.zacks.com/stock/news/847430/lillys-taltz-gets-fda-nod-for-plaque-psoriasis-in-children?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-847430 Mar 31, 2020 - The FDA approves Eli Lilly's (LLY) sBLA for Taltz injection to treat pediatric patients with moderate to severe plaque psoriasis. Stock up. 0

http://www.zacks.com/stock/news/845462/aveo-stops-aml-study-on-ficlatuzumab-amid-coronavirus-pandemic?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-845462 Mar 30, 2020 - AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia to combat the COVID-19 outbreak. 0

http://www.zacks.com/stock/news/838749/bristol-myers-bmy-clinches-fda-nod-for-ms-drug-zeposia?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-838749 Mar 27, 2020 - The FDA approves Bristol Myers' (BMY) Zeposia for the treatment of adults with relapsing forms of multiple sclerosis. 0

http://www.zacks.com/stock/news/834155/pfizers-eczema-drug-eucrisa-gets-fda-approval-for-infants?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-834155 Mar 25, 2020 - Pfizer (PFE) gets FDA approval for label expansion of Eucrisa to include children aged three months to two years with mild-to-moderate atopic dermatitis or eczema. 0

https://www.fool.com/investing/2020/03/25/3-reasons-pharma-stocks-are-a-buy-right-now.aspx?source=iedfolrf0000001 Mar 25, 2020 - The coronavirus outbreak has made shares of top drugmakers more attractive than they've been in a quite a while. 0

http://www.zacks.com/stock/news/832392/agios-ind-for-pkr-activator-ag-946-gets-fda-clearance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-832392 Mar 24, 2020 - The FDA passes Agios' (AGIO) investigational new drug application for its next-generation PKR activator, AG-946. The company plans to begin a phase I study on the same in mid-2020. 0